Treatment of hypercholesterolemia with the HMG CoA reductase inhibitor, simvastatin

Cardiovascular Drugs and Therapy
G M BergerB I Joffe

Abstract

We report the results of a two center study on the use of the HMG Co A reductase inhibitor, simvastatin, in 44 patients suffering from familial hypercholesterolemia or from primary hypercholesterolemia of unknown etiology. The study included two separate phases: Phase I was part of a multicenter, 4-week, placebo-controlled trial; phase II was a 6-month, open extension trial, the object of which was to reduce low density lipoprotein (LDL) cholesterol levels to below the 50th percentile by increasing the dose of simvastatin, by the use of additional lipid-lowering medication, or both. Our phase I results were commensurate with those reported for the entire international cohort of 272 patients, indicating a clear dose-response relationship, with approximately 75% of the maximum reduction in LDL-C levels being achieved with 20 mg/day and over 90% of the maximum being achieved with 40 mg of simvastatin per day. In the open extension trial, the results from the 2 centers were essentially similar. Total cholesterol fell by 29% on the 20 mg/day dose and by 34% on the full dose of 40 mg/day. LDL-C levels were reduced by 40% on the 40 mg/day schedule, and triglycerides also fell to between 20% and 40% below baseline values. HDL-C concent...Continue Reading

References

Jan 1, 1979·Archives of Biochemistry and Biophysics·J R FaustM S Brown
Jun 12, 1987·JAMA : the Journal of the American Medical Association·N NakayaY Goto
Jan 7, 1988·The New England Journal of Medicine·C V BroomeA W Hightower
Jan 7, 1988·The New England Journal of Medicine·D J NormanJ Hosenpud
Jan 7, 1988·The New England Journal of Medicine·C EastJ A Farmer
Jul 7, 1988·The New England Journal of Medicine·S M Grundy
Jan 15, 1988·JAMA : the Journal of the American Medical Association·D B HunninghakeJ A Tobert
Apr 15, 1986·The American Journal of Cardiology·J M HoegD L Sprecher
Jan 2, 1987·JAMA : the Journal of the American Medical Association·G L Vega, S M Grundy
Jan 1, 1987·Medical Toxicology·L C Knodel, R L Talbert
Feb 1, 1986·Metabolism: Clinical and Experimental·C A EastD W Bilheimer
Apr 1, 1987·The American Journal of Cardiology·J M HoegH B Brewer
Dec 1, 1986·Journal of the American College of Cardiology·P L CannerW Friedewald
Feb 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·P T KovanenM S Brown
Aug 27, 1981·The New England Journal of Medicine·M S Brown, J L Goldstein
Dec 1, 1984·The Journal of Clinical Investigation·D R Illingworth, G J Sexton
Jul 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·D W BilheimerJ L Goldstein
Oct 14, 1983·JAMA : the Journal of the American Medical Association·B M Rifkind, P Segal
Jul 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·A W AlbertsJ Springer
Mar 1, 1980·Atherosclerosis·A YamamotoA Endo

❮ Previous
Next ❯

Citations

Jan 1, 1993·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·M FukamiY Tsujita
Dec 16, 1991·Clinica Chimica Acta; International Journal of Clinical Chemistry·S P ZhaoA van der Laarse
May 19, 2006·Proceedings of the National Academy of Sciences of the United States of America·Ryan B Corcoran, Matthew P Scott
Jan 15, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Rhian M Touyz
Mar 4, 2014·Journal of Atherosclerosis and Thrombosis·Shen LiJianglin Fan

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.